<DOC>
	<DOCNO>NCT02436733</DOCNO>
	<brief_summary>This multicenter , randomize , 1:1 , non-comparative phase II trial . Patients early stage MPM randomize Arm A : immediate P/D follow three cycle chemotherapy ( pemetrexed 500mg/m2 cisplatin 75 mg/m2 , drug give day 1 , every three week ) Arm B : three cycle chemotherapy ( regimen ) follow P/D , non-progressing patient</brief_summary>
	<brief_title>Pleurectomy/ Decortication ( P/D ) Preceded Followed Chemotherapy Patients With Early Stage MPM</brief_title>
	<detailed_description>This academic lead , multicenter , randomize , 1:1 , non-comparative phase II trial . Patients early stage MPM randomize - Arm A - immediate surgery : immediate P/D follow three cycle chemotherapy ( pemetrexed 500mg/m2 cisplatin 75 mg/m2 , drug give day 1 , every three week ) non-progressing patient - Arm B - delay surgery : three cycle chemotherapy ( regimen ) follow P/D , non-progressing patient . A maximum four week ( ±2 week ) allow baseline tumor assessment start treatment ( surgery chemotherapy ) . Randomization do soon possible baseline tumor assessment . The primary objective study investigate feasibility immediate P/D follow cisplatin/pemetrexed chemotherapy defer P/D cisplatin/pemetrexed chemotherapy patient early stage MPM . The result study allow LCG take one arm comparative study either surgery EPP control arm . The choice comparator depend result parallel ongoing randomize study UK , compare P/D surgery</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients age 18 year old , pathologically proven malignant pleural mesothelioma . All histological subtypes accept . Stage cT13 , N02 , M0 accord UICC TNM classification . FDGPETCT scan show absence M1 , N3 , supraclavicular coeliac node involvement require . No clinical invasion mediastinal structure ( heart , aorta , spine , esophagus , etc . ) widespread chest wall invasion ( T4 ) acceptable . Focal chest wall lesion acceptable . No prior treatment kind mesothelioma allow , especially prophylactic track irradiation diagnostic procedure . WHO performance status 01 Fit receive chemotherapy undergo pleurectomy/ decortication optional removal hemidiaphragm pericardium . No history malignancy within last three year , except carcinoma situ cervix basal cell spinocellular carcinoma skin . No preexist peripheral sensory motor neuropathy &gt; grade I accord CTCAE v4.0 No clinically significant pleural effusion manage thoracentesis pleurodesis ( accord institutional practice ) . If pleurodesis consider , do randomization . Adequate organ function Women child bear potential must negative serum ( urine ) pregnancy test within 3 day prior start chemotherapy/surgery . Patients childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least three month last study treatment . Before patient registration write informed consent must give accord ICH/GCP , national/local regulation . Exclusion Criteria • Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , metabolic disease ; wound heal disorder ; ulcer ; bone fracture , know infection HIV , active hepatitis B and/or hepatitis C virus ) . significant cardiovascular morbidity ( assessed cardiologist ) precluding surgery Major surgical procedure significant traumatic injury within 28 day prior randomization anticipation need major surgery ( P/D ) course study treatment . History receive investigational treatment within 28 day randomization . History intolerance pemetrexed and/or cisplatin . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pleural mesothelioma</keyword>
	<keyword>phase II</keyword>
	<keyword>randomize</keyword>
	<keyword>surgery</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>feasibility</keyword>
</DOC>